First in Human Study of YB1-X7 Injection

NCT06889675 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: YB1-X7 Injection (IT)
DRUG: YB1-X7 Injection (IV)

Sponsor

Shanghai Salvectors Biotechnology LTD.